Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Key Govt Panel Meets to Discuss Brexit’s Impact on Industries
June 29, 2016
- AMED Sets Up First Overseas Outpost in Singapore
June 28, 2016
- MHLW Vows to Forge Ties with UK Counterpart in Post-Brexit Regulations
June 27, 2016
- JEC Rengo Petitions MHLW to Eliminate “Huge-Seller” Repricing in Its Policy Proposal
June 27, 2016
- Panel to Discuss Zoster Vaccine’s Add’l Use, DPT Vaccine’s Booster Dose for Public Immunization Program
June 24, 2016
- Registration System for Prevention of Dementia to Begin Operation; Will Provide Info on Clinical Research, Trials
June 24, 2016
- MHLW Official Vows to Swiftly Present Proposal on “Optimal Use of Innovative Drugs”: Chuikyo
June 23, 2016
- Chuikyo OKs NHI Price Listing of Anti-HIV Drug Genvoya
June 23, 2016
- Exemption from Bioequivalence Studies Adopted as New Topic at ICH Meeting in Lisbon; Could Affect Generics as Well
June 22, 2016
- Selexipag Designated as Orphan Drug for CTEPH: MHLW
June 21, 2016
- PMDA to Boost Transparency in Expert Consultation Process by Confirming Donations from Competitors
June 21, 2016
- PMDA Beats FY2015 Review Time Targets
June 20, 2016
- MHLW Unveils List of Switch OTCs Eligible for Tax Break
June 20, 2016
- Anti-HIV Drug Genvoya Approved in Japan
June 20, 2016
- MHLW Reprimands Bipha Over Leakage of Recombinant Organisms in Manufacturing Process for Medway Injection
June 20, 2016
- Kaketsuken-Like Cases Seen Outside Japan Too, Many Exposed through Tip-Offs: PMDA
June 17, 2016
- MHLW Study Group Approves Interim Report toward Full-Scale Operation of MID-NET Database
June 17, 2016
- First Generics for 8 APIs to Join NHI Price List on June 17, 40% Price Rule Applied to Olanzapine
June 16, 2016
- Greater than Expected Need for Drug Discovery Research Using Existing Drugs: AMED Project
June 16, 2016
- MHLW Personnel Reshuffle Announced; Nakayama to Lead FY2018 Drug Pricing Reform
June 15, 2016
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…